Home Antibody All anti-TNFSF10 antibodies
Also for TNFSF10 (NM_003810)
|TRAIL antibody was raised against a peptide corresponding to amino acids near the carboxy terminus of human TRAIL.|
||WB: 1 ug/ml
|PBS containing 0.02% sodium azide.|
|Ion exchange chromatography purified
|Homo sapiens tumor necrosis factor (ligand) superfamily, member 10 (TNFSF10), transcript variant 1|
|Apo-2L; APO2L; CD253; TL2; TRAIL|
|Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel member in the TNF family was recently identified and designated TRAIL (for TNF-related apoptosis-inducing ligand) and Apo-2L (for Apo-2 ligand)1,TRAIL is a type II membrane protein and expressed in a variety of human tissues. Two novel death domain containing receptors DR4 and DR5 have been identified as the receptor for TRAIL3-6. Like TNF and Fas ligand, TRAIL induces apoptosis and NF-kappaB activation in many tissues and cells.|
Cytokine-cytokine receptor interaction
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis of TRAIL in HeLa cell lysate containing 10, 2.5, or 1 ng of recombinant protein containing extracellular domain of TRAIL with TRAIL antibody at 1 ug/ml.
Immunohistochemistry of TRAIL in human brain tissue with TRAIL antibody at 20 ug/ml.